Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility.
Kerins
D M
DM
Murray
R
R
FitzGerald
G A
GA
D000262:Adenylyl Cyclases / Q000378:metabolism; D000328:Adult; D000527:Alprostadil / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D003327:Coronary Disease / Q000188:drug therapy; D004311:Double-Blind Method; D004341:Drug Evaluation; D004361:Drug Tolerance; D004373:Ductus Arteriosus / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D011464:Epoprostenol / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D005112:Extracorporeal Circulation / Q000009:adverse effects; D006330:Heart Defects, Congenital / Q000188:drug therapy; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D007223:Infant; D007231:Infant, Newborn; D010974:Platelet Aggregation / Q000187:drug effects; D011928:Raynaud Disease / Q000188:drug therapy; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin / Q000378:metabolism; D018078:Receptors, Prostaglandin E; D006435:Renal Dialysis / Q000009:adverse effects; D015290:Second Messenger Systems; D013921:Thrombocytopenia / Q000209:etiology / Q000517:prevention & control; D014652:Vascular Diseases / Q000188:drug therapy
D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin; D018078:Receptors, Prostaglandin E; D011464:Epoprostenol; D000262:Adenylyl Cyclases; D000527:Alprostadil